SCHEMBL348286

SCHEMBL348286

CCOC(=O)C(C(=O)O)c1cc(Cl)cc(OCc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MRGPRX4 Q96LA9 2/20 0.47
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
ALDH1A1 P00352 1/20 0.44
FFAR1 O14842 2/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSP90AA1 P07900 1/20 0.42
RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348285 0.86 MRGPRX4 (0.50) LMNAL3MBTL1MRGPRX4KMT2AMEN1
SCHEMBL27900716 0.82 LMNA (0.65) LMNAL3MBTL1NR1H4ALDH1A1FFAR1
SCHEMBL7811580 0.81 LMNA (0.53) LMNAL3MBTL1KMT2AMEN1NR1H4
SCHEMBL2716599 0.77 LMNA (0.68) LMNAL3MBTL1NR1H4ALDH1A1FFAR1
SCHEMBL137417 0.77 MAOB (0.54) LMNAL3MBTL1MRGPRX4KMT2AMEN1
SCHEMBL27799848 0.76 MRGPRX4 (0.49) MRGPRX4KMT2AMEN1SMN1; SMN2RXRA
SCHEMBL491296 0.74 LMNA (0.46) LMNAL3MBTL1KMT2AMEN1NR1H4
SCHEMBL3485036 0.74 KMT2A (0.56) LMNAL3MBTL1KMT2AMEN1FFAR1
SCHEMBL153724 0.74 MMP8 (0.42) LMNAL3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL4951331 0.74 KMT2A (0.53) LMNAL3MBTL1KMT2AMEN1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247602-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-21 US disclosed
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2012-01-19 US disclosed
US-8071807-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2011-12-06 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-06-16 US disclosed
EP-2307362-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010003120-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 LMNA 2277/4885L3MBTL1 4068/4885MRGPRX4 107/4885
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 LMNA 2277/4885L3MBTL1 4068/4885MRGPRX4 107/4885
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 LMNA 2277/4885L3MBTL1 4068/4885MRGPRX4 107/4885
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 LMNA 2161/4885L3MBTL1 4395/4885MRGPRX4 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.